Abstract
ObjectivesAs part of a randomised controlled trial, this qualitative study aimed to identify experiences and challenges of hospitalised patients with COVID-19 during illness and treatment (objective 1: COVID-19-related perspectives; objective 2: trial participation-related perspectives).DesignSemistructured interviews following a prespecified interview guide, transcribed verbatim and analysed in accordance with the grounded theory process. Investigator triangulation served to ensure rigour of the analysis.SettingInterviews were embedded in a multicentre, randomised, active-controlled, open-label platform trial testing efficacy and safety of experimental therapeutics for patients with COVID-19 (Austrian Corona Virus Adaptive Clinical Trial).Participants20 patients (60±15 years) providing 21 interviews from 8 June 2020 to 25 April 2021.ResultsQualitative data analysis revealed four central themes with subthemes. Theme 1, ‘A Severe Disease’, related to objective 1, was characterised by subthemes ‘symptom burden’, ‘unpredictability of the disease course’, ‘fear of death’ and ‘long-term aftermaths with lifestyle consequences’. Theme 2, ‘Saved and Burdened by Hospitalization’, related to objective 1, comprised patients describing their in-hospital experience as ‘safe haven’ versus ‘place of fear’, highlighting the influence of ‘isolation’. Theme 3, ‘Managing One’s Own Health’, related to objective 1, showed how patients relied on ‘self-management’ and ‘coping’ strategies. Theme 4, ‘Belief in Medical Research’, related to objective 2, captured patients’ ‘motivation for study participation’, many expressing ‘information gaps’ and ‘situational helplessness’ in response to study inclusion, while fewer mentioned ‘therapy side-effects’ and provided ‘study reflection’. Investigator triangulation with an expert focus group of three doctors who worked at the study centre confirmed the plausibility of these results.ConclusionsSeveral of the identified themes (2, 3, 4) are modifiable and open for interventions to improve care of patients with COVID-19. Patient-specific communication and information is of utmost importance during clinical trial participation, and was criticised by participants of the present study. Disease self-management should be actively encouraged.Trial registration numberNCT04351724.
Funder
Medical-scientific fund of the Mayor of the federal capital Vienna
Austrian Science Fund
Reference39 articles.
1. SARS-CoV-2 is an appropriate name for the new coronavirus;Wu;Lancet,2020
2. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
3. ClinicalTrials.gov , 2021. Available: https://clinicaltrials.gov/ct2/covid_view [Accessed 01 November 2021].
4. COVID-19 Treatment Guidelines Panel . Coronavirus disease 2019 (COVID-19) treatment guidelines, 2022. National Institutes of health. Available: https://www.covid19treatmentguidelines.nih.gov/ [Accessed 12 January 2022].
5. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial;Ehrmann;Lancet Respir Med,2021